Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimizing the potential of antibody-drug conjugates in oncology.
Mosele F, Montagnac G, Pistilli B, André F. Mosele F, et al. Among authors: pistilli b. Ann Oncol. 2023 Nov;34(11):964-967. doi: 10.1016/j.annonc.2023.08.020. Epub 2023 Sep 19. Ann Oncol. 2023. PMID: 37730120 No abstract available.
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J. Campone M, et al. Among authors: pistilli b. Eur J Cancer. 2018 Nov;103:147-154. doi: 10.1016/j.ejca.2018.08.002. Epub 2018 Sep 18. Eur J Cancer. 2018. PMID: 30241001 Clinical Trial.
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M. Campone M, et al. Among authors: pistilli b. Eur J Cancer. 2013 Aug;49(12):2621-32. doi: 10.1016/j.ejca.2013.04.011. Epub 2013 Jun 1. Eur J Cancer. 2013. PMID: 23735704 Free article.
Pregnant with metastatic neuroendocrine tumour of the ovary: what now?
Pistilli B, Grana C, Fazio N, Cavaliere A, Ferrari M, Bodei L, Baio S, Scambia G, Paganelli G, Peccatori F. Pistilli B, et al. Ecancermedicalscience. 2012;6:240. doi: 10.3332/ecancer.2012.240. Epub 2012 Jan 3. Ecancermedicalscience. 2012. PMID: 22331988 Free PMC article.
"Short Course" of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07).
Rossi D, Pistilli B, Morale D, Baldelli, Casadei V, Benedetti G, Alessandroni P, Catalano V, Giordani P, Graziano F, Fedeli SL, Fiorentini G. Rossi D, et al. Among authors: pistilli b. World J Oncol. 2011 Oct;2(5):245-251. doi: 10.4021/wjon393w. Epub 2011 Oct 28. World J Oncol. 2011. PMID: 29147255 Free PMC article.
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Beck JT, et al. Among authors: pistilli b. Breast Cancer Res Treat. 2014 Feb;143(3):459-67. doi: 10.1007/s10549-013-2814-5. Epub 2013 Dec 21. Breast Cancer Res Treat. 2014. PMID: 24362951 Free PMC article. Clinical Trial.
124 results